Glycated Albumin Combined With Body Composition for Gestational Diabetes Mellitus Prediction
Status
Conditions
Details and patient eligibility
About
This study is going to investigate the predictive ability of glycated albumin combined with body composition, including body weight, BMI, fat free mass and fat mass for gestational diabetes mellitus (GDM) diagnosis.
Full description
The prevalence of GDM is increasing all over the world. It has bad influence for both pregnant women and fetus. Early treatment is useful for GDM prevention. Therefore early screening is important for healthcare doctors to detect the potential patients. Glycated albumin (GA) is an optimal index for blood glucose evaluation compared to HbA1c, however it may be influenced by body weight and composition. The investigators are going to investigate the predictive ability of glycated albumin combined with body composition, including body weight, BMI, fat free mass and fat mass for gestational diabetes mellitus (GDM) diagnosis. This study recruit pregnant women before 12 weeks of their pregnant age and test GA level and body composition via bioelectrical impedance analysis. During 24-28 weeks of pregnant age, all participants will do the glucose tolerant test for GDM diagnosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age between 20-45
- Healthy, without heart disease, liver or kidney dysfunction, immune system or metabolic or infectious disease,
Exclusion criteria
- Diabetes that appeared before pregnancy
- Pregnant with medical disease, such as asthma, hypertension, cardiovascular diseases, kidney diseases or liver disease.
- Hormone use in the recent 1 year
- Assisted reproduction pregnancy
- Multiple births
- Cannot complete the blood test or body composition examination
Trial design
300 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Fang Wang, MD; Kang Yu, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal